Print Page  Close Window
10-Q
PARATEK PHARMACEUTICALS, INC. filed this Form 10-Q on 05/09/2018
Entire Document
 

 

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except for share and par value amounts)

(unaudited)

 

 

 

March 31,

2018

 

 

December 31,

2017

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

49,273

 

 

$

35,416

 

Available-for-sale securities

 

 

135,051

 

 

 

116,307

 

Restricted cash

 

 

229

 

 

 

162

 

Accounts receivable

 

 

50

 

 

 

5,041

 

Other receivable

 

 

785

 

 

 

848

 

Prepaid and other current assets

 

 

2,840

 

 

 

2,712

 

Total current assets

 

 

188,228

 

 

 

160,486

 

Restricted cash

 

 

250

 

 

 

250

 

Fixed assets, net

 

 

1,583

 

 

 

1,711

 

Intangible assets, net

 

 

139

 

 

 

142

 

Goodwill

 

 

829

 

 

 

829

 

Other long-term assets

 

 

263

 

 

 

280

 

Total assets

 

$

191,292

 

 

$

163,698

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,756

 

 

$

3,555

 

Other accrued expenses

 

 

6,938

 

 

 

8,270

 

Accrued contract manufacturing costs

 

 

5,064

 

 

 

4,964

 

Current portion of long-term debt

 

 

7,607

 

 

 

 

Total current liabilities

 

 

23,365

 

 

 

16,789

 

Long-term debt

 

 

51,684

 

 

 

59,186

 

Contingent obligations

 

 

56

 

 

 

71

 

Other liabilities

 

 

5,420

 

 

 

5,174

 

Total liabilities

 

 

80,525

 

 

 

81,220

 

Commitments and contingencies (Note 15)

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock:

 

 

 

 

 

 

 

 

Undesignated preferred stock: $0.001 par value; 5,000,000 shares authorized;

   no shares issued and outstanding

 

 

 

 

 

 

Common stock, $0.001 par value; 100,000,000 shares authorized; 31,443,149 and

   27,941,015 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively

 

 

31

 

 

 

28

 

Additional paid-in capital

 

 

608,776

 

 

 

552,720

 

Accumulated other comprehensive loss

 

 

(180

)

 

 

(158

)

Accumulated deficit

 

 

(497,860

)

 

 

(470,112

)

Total stockholders’ equity

 

 

110,767

 

 

 

82,478

 

Total liabilities and stockholders’ equity

 

$

191,292

 

 

$

163,698

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

2